New ibuzatrelvir tablet put to the test in healthy volunteers

NCT ID NCT07552779

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 6 times

Summary

This early-stage study is testing a new tablet version of the COVID-19 drug ibuzatrelvir in 18 healthy adults. Researchers want to see how much of the drug gets into the blood when taken as a whole tablet, dispersed in water, or with food. The goal is to compare the new tablet to the original one. Participants will stay in a clinic for about 10 days and be followed for 11 weeks total.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibuzatrelvir
What this could lead to: If successful, this could lead to a more convenient or effective tablet form of ibuzatrelvir for treating COVID-19.
What could go wrong: This is a very early Phase 1 study with only 18 healthy people, not patients. It only measures drug levels in blood, not whether the drug actually treats COVID-19. The new tablet may not work better than the original.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONAVIRUS DISEASE 2019 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 Infections lung disorder pneumonia respiratory system disorder respiratory tract infectious disorder RNA Virus Infections viral pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONAVIRUS DISEASE 2019 CORONAVIRUS DISEASE 2019 (COVID-19) COVID-19 COVID-19 (CORONAVIRUS DISEASE 2019) COVID-19 INFECTION COVID-19 SARS-COV-2 INFECTION LUNG DISEASES PNEUMONIA RESPIRATORY TRACT DISEASES RESPIRATORY TRACT INFECTION UPPER RESPIRATORY TRACT INFECTIONS

Contacts and locations

Locations

Pfizer Clinical Research Unit - Brussels

Brussels, Bruxelles-capitale, Région de, B-1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.